Study links anemia drugs to fatal blood clots

11/11/2009 | U.S. News & World Report

Researchers found that cancer patients who received erythropoiesis-stimulating agents, such as Procrit and Aranesp, to prevent chemotherapy-related anemia were more likely to develop deep vein thrombosis or pulmonary embolism than those who did not receive the drugs. The results raise concerns regarding the approval process and postmarketing research conducted to ensure long-term safety of such drugs, the lead researcher said.

View Full Article in:

U.S. News & World Report

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY